Overview

A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Investigate safety and tolerability of the escalating dose of CAM-3001 in patients.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune Ltd
Treatments:
Antibodies, Monoclonal
Mavrilimumab